Article

Targeting homologous recombination repair in BCR/ABL1-positive cells using PARP inhibitor

2022-12-05

Abstract excerpt

BCR/ABL1 causes dysregulated cell proliferation and is responsible for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). In addition to the deregulatory effects of its kinase activity on cell proliferation, BCR/ABL1 induces genomic instability by downregulating BRCA1. PARP inhibitors (PARPi) effectively induce cell death in BRCA-defective cells. Therefo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8d0621eb-9b01-56a3-98bd-6f035be6cfa9
DOI: 10.21203/rs.3.rs-2324754/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting homologous recombination repair in BCR/ABL1-positive cells using PARP inhibitorDOI 10.21203/rs.3.rs-2324754/v1Read

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategiesSemantic proximity Read

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged SwordSemantic proximity Read

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.Semantic proximity Read

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.Semantic proximity Read

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsSemantic proximity Read

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.Semantic proximity Read

High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsSemantic proximity Read

CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.Semantic proximity Read

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma EffectsSemantic proximity Read

Targeting ATM-deficient CLL through interference with DNA repair pathwaysSemantic proximity Read

Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein–Barr virusSemantic proximity Read